2nd Edition of Global Conference on Surgery and Anesthesia

September 28-30, 2020 | Paris, France

Campanile Roissy-En-France Hotel
Roissy Park Activity Area - Allee Des Vergers 95700 Roissy In France
Phone : 1 (702) 988 2320
Toll Free: 1800–883-8082
Whatsapp: +1 434 381 1007
Email: contact@surgery-conferences.com
September 28-30, 2020 | Paris, France

Agnese Ozolina

Keynote speaker for surgery conference - Agnese Ozolina
Agnese Ozolina
Rigas Stradins University ,Lativia
Title : Up-to-date of thromboprophylaxis in orthopedic/spine surgery


Orthopedic patients are among those at highest risk of developing post-operative venous thromboembolic complications. In an orthopaedic patient all processes described in the Virchow’s triad in 1884 are presented. Symptomatic venous thromboembolism (VTE) within three months without TE prophylaxis are in the range of 1.3 to 10 %. Therefore, anticoagulant is essential for those patients. There are still discussions about the right choice of anti-coagulant are going on. Factor Xa inhibitor is the compound that has increased the most as anti-coagulant (annual growth rate of 43%) in orthopedic patients followed by aspirin (30%). Nevertheless, the National Institute of Health and Care Excellence  (NICE) study and the European guidelines on perioperative prophylaxis against venous thromboembolism of 2018 recommend low molecular weight heparin (LMWH) and Aspirin. This leaves direct oral anticoagulants (DOACs) as alternative for preventing deep vain thrombosis (DVT) in orthopedic patients. We are still seeking consensus in perioperative anticoagulation in orthopedic patients and particularly in those undergoing major spinal surgery. For the latter patients, at hight risk of contracting VTE, the American college of chest physicians (ACCP) in 2012 recommended prophylaxis with LMWH. However, still some questions remain; when is the optimal time to start prophylactic treatment and for how long time should it continue? Would it be more preferable to administer oral anticoagulants? Although, there is still a lack of evidence concerning DOACs in major spinal surgery, numerous reports and ongoing trials are available presenting their data of DOACs in comparison with LMWH in spinal patients at hight risk of contracting VTE.


Dr. med, PhD Agnese Ozolina studied in R?gas Stradi?š University Medical faculty and graduated as MD in 2004. Then she continued training in Anaesthesia and Intensive Care medicine becoming a specialist in 2010. My greatest interest has always been directed toward to the management of bleeding and thrombosis. A growing interest in research and lecturing, led me to a prospective observational study on genetically determinated fibrinolytic bleeding after cardiac surgery, which founded the basis of my dissertation and PhD degree in 2013. Consequently, several publications were reported. Parallel, I have an experience as invited lecturer in local and international meetings. As assistant professor of R?gas Stradi?š University I am involved in teaching of physiological and pathophysiological aspects of haemostasis in local and international students. Presently, I am the head of Anaesthesiology at Riga East University hospital. Paralelly, I am mostly involved in the regional anesthesia techniques and management of haemostasis in orthopaedic and microvascular free flap surgery patients, including such essentials as individual goal-directed treatment based on ROTEM analysis for bleeding as well as for anticoagulation management.